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ABSTRACT
Administration of nicotinamide is affecting various types of cells through its survival, maturation, and differentiation. 
Nicotinamide as part of vitamin B3, plays an important role in DNA repair and  maintenance of the genomic stability 
which related to its function as a NAD+ precursor that involve in many biological processes. During DNA breaks, 
PARP-1 mechanism will be activated and use NAD+ as a substrate in process of DNA damage and repair that will result 
to either cell repair and cell death. In the meantime, in presence of nicotinamide that is also acting as a PARP-1 inhibitor, 
causing inability of the repair mechanism to fix the entire DNA damage which also lead to the cell death. Therefore, 
loss of PARP-1 enzyme will cause disturbance in the DNA repair process. Telomere shortening rate was reduced in the 
presence of nicotinamide that might related with telomerase enzyme which able to maintain the telomere length of the 
cell. Other than that, telomere also can be influenced by PARP-1 activity where it might show some correlation between 
nicotinamide, telomere and telomerase that could related with PARP-1 mechanism. Currently, there is no treatment 
options that respond effectively in chronic myeloid leukemia (CML) in blast crisis (BC) phase without any side effect 
and it is require an identification of new drug therapies to treat the CML patients. By understanding the role and potential 
of nicotinamide relation with PARP-1 mechanism in telomere and telomerase status may improve the therapeutic 
strategy for chronic myeloid leukemia.
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ABSTRAK
Pengambilan nikotinamida menjejaskan pelbagai jenis sel melalui kelangsungan hidup, kematangan dan 
pembezaannya. Nikotinamida sebagai sebahagian daripada vitamin B3 memainkan peranan penting dalam 
pembaikan dan penyelenggaraan kestabilan genom DNA yang berkaitan dengan fungsinya sebagai prakursor NAD+ 
yang melibatkan banyak proses biologi. Semasa DNA pecah, mekanisme PARP-1 akan diaktifkan dan menggunakan 
NAD+ sebagai substrat dalam proses kerosakan dan pembaikan DNA yang akan menyebabkan pembaikan sel 
dan kematian sel. Sementara itu, dengan adanya nikotinamida yang juga bertindak sebagai perencat PARP-1, 
menyebabkan ketidakupayaan mekanisme pembaikan untuk memperbaiki keseluruhan kerosakan DNA yang juga 
membawa kepada kematian sel. Oleh itu, kehilangan enzim PARP-1 akan menyebabkan gangguan dalam proses 
pembaikan DNA. Kadar pemendekan telomer berkurang dengan kehadiran nikotinamida yang mungkin berkaitan 
dengan enzim telomerase yang dapat mengekalkan panjang telomer sel. Selain itu, telomer juga boleh dipengaruhi 
oleh aktiviti PARP-1 dan ia mungkin menunjukkan beberapa korelasi antara nikotinamida, telomer dan telomerase 
yang boleh dikaitkan dengan mekanisme PARP-1. Pada masa ini, tiada pilihan rawatan yang bertindak balas dengan 
berkesan dalam leukemia mieloid kronik (CML) dalam fasa krisis blas (BC) tanpa sebarang kesan sampingan dan 
memerlukan pengenalan terapi ubat baru untuk merawat pesakit CML. Dengan memahami peranan dan potensi 
hubungan nikotinamida dengan mekanisme PARP-1 dalam telomer dan status telomerase dapat meningkatkan 
strategi terapeutik untuk leukemia mieloid kronik.
Kata kunci: Nikotinamida; PARP-1; telomerase; telomer
INTRODUCTION
Nicotinamide or known as niacinamide or nicotinic acid 
amide is an active form of vitamin B3 which is also a water 
soluble amide of nicotinic acid with many physiological 
and pharmacological functions in various organisms. It 
acts as precursors of nicotinamide adenine dinucleotide 
(NAD) (Audrito et al. 2011) which is an important molecule 
involve in energy metabolism and also in chemical 
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reaction in the body including ADP-ribosylation that 
related to DNA repair, cell death, transcription, DNA 
replication, and cell cycle (Ida et al. 2009). Nicotinamide 
has also shown to be a free radical scavenger and been 
used in cyclic ADP ribose synthesis (Surjana et al. 2010) 
and its phosphorylated derivative, nicotinamide adenine 
dinucleotide phosphate (NADP+). The dietary sources of 
nicotinamide and niacin are readily available in plant and 
animal food such as in liver, yeast, dairy product, bean, 
green vegetable, bread and coffee. NAD+ and NADP+ 
can be enzymatically hydrolyzed to nicotinamide from 
the uncooked food during the process of cooking (Jacob 
& Swendseid 1996).
Nicotinamide have been used for years by many people 
and it was shown to have low toxicity and side effects 
(Knip et al. 2000). Deficiency of nicotinamide in human 
can cause pellagra (Bogan & Brenner 2008) which is a 
nutritional disorder to cause dermatitis, diarrhea, dementia, 
and also death (Karthikeyan & Thappa 2002). It also had 
been used in the therapy of pellagra even in high levels of 
the drugs. According to Paul (2011), nutrient deficiency 
such as folate, zinc and magnesium, can cause the DNA 
damage from various causes possibly results to shorter 
telomeres in rats and cells.
Cancer patients were found to be at risk of niacin 
deficiency in a few studies due to the suppressed 
NAD+ levels from chemotherapy and maintaining an 
optimum level of nicotinamide is therefore important 
to these patients (Surjana et al. 2010). On the other 
hand, nicotinamide also functions as sensitizing agent 
and counteract chemotherapy and radiation therapy by 
increasing blood flow that will allow the elevated oxygen 
supply to the tumors (De Soto et al. 2006). Thus, tumors 
hypoxia is reduced.
Based on the study by Chen et al. (2015), this one type 
of vitamin B3 has also been shown to have the ability to 
preserve from the effects caused by the UV radiation and 
thus decrease the proportion for new premalignant skin 
cancer. They have found that nicotinamide has reduced 
the rate of various type of skin cancers when treated with 
nicotinamide from 11-30% compared to other type of 
treatment and no evidence benefit after discontinuation 
of nicotinamide. They also have come to agree that the 
intake of oral nicotinamide was safe and effective to 
be used in the treatment of high-risk patient of skin 
cancer. UV radiation can cause damage to DNA, disturb 
the immunity system (Yarosh 2004) and depleting the 
cellular ATP thereby inhibiting the DNA repair (Park 
et al. 2010). The production of ATP that can be used 
for DNA repair requires NAD+ which can be obtain 
from nicotinamide that also act as a precursor of NAD+. 
Therefore, glycolytic blockade, ATP depletion and also 
the level of immunosuppression caused directly by the UV 
radiation can be reduced and prevented by nicotinamide 
(Park et al. 2010; Surjana et al. 2013; Thompson et al. 
2014; Yarosh 2004). Nicotinamide has been proven to 
play a beneficial role in inhibiting liver fibrosis in rats and 
at the same time able to induce apoptosis by reducing the 
expression in cell cycle related proteins (Jin et al. 2011; 
Traister et al. 2005).
Over years, nicotinamide has been used within 
required doses with minimal side effect that does not cause 
flushing, itching, hypotension or headaches under doses 
of consumption (Knip et al. 2000; Ranchoff & Tomecki 
1986). Nicotinamide is also an inexpensive supplement 
that widely accessible in any pharmacies which can be 
taken as an additional supplement for consumption.
Moreover, nicotinamide also play an important role 
in poly (ADP-ribose) polymerase (PARP-1) which has 
a part in reassembling the DNA strand breaks caused 
by radiation and chemotherapy (Kjellen et al. 1985). Its 
function as NAD+ precursor and also a substrate for PARP-
1 has been an important player in DNA repair and also 
maintenance of the genomic stability as the increase of 
NAD+ level by addition of nicotinamide will also increase 
and improve the capacity in DNA repair. It has been 
studied that a certain amount of nicotinamide increase 
the intracellular NAD+ and enhance the repair of DNA 
damage in cultured primary human mammary epithelial 
cells (Jacobson et al. 1999). It is essential to have adequate 
NAD+ for the increase in ADP-ribose polymer metabolism 
due to the DNA damage. Hence, it showed that increasing 
level of NAD+ by addition of nicotinamide therefore 
improved the capacity of DNA repair. Even a poor diet 
can fulfill the standard requirement for NAD+ synthesis 
since NAD+ has various precursors (Belenky et al. 2007). 
As in the case of pellagra, it is clear it could be harmful 
in a shortage of NAD, yet it is remains to be seen whether 
high dosages of NAD precursors can be applicable as a 
therapeutic or as beneficial diet supplements. This review 
aims to highlight better understanding of the potential 
association of nicotinamide on the telomerase activity 
and telomere length mediated by PARP-1 mechanism 
particularly in myeloid cancer and to initiate further 
investigation of tyrosine kinase inhibitors such as nilotinib 
in relation to nicotinamide supplementation effects.
NICOTINAMIDE AND PARP-1 MECHANISM
Administration of poly (ADP-ribose) polymerase 1 
(PARP-1) has been developed to be one of the promising 
molecular targets as an anticancer drug where it involves 
in many biological process from DNA repair to cell death. 
PARP-1 is also known as NAD+ ADP-ribosyltransferase 
is a nuclear enzyme encoded by PARP-1 gene which 
used in DNA damage and repair, where it binds to the 
DNA single or double strand breaks and used NAD+ 
as a substrate to form a nicotinamide and ADP-ribose 
(De Lorenzo et al. 2013; Surjana et al. 2010). One 
of the earliest events that occur when DNA breaks is 
the recognition of DNA damage by PARP-1 enzyme 
(Malyuchenko et al. 2015). DNA breaks will activated 
the PARP-1 which can lead to three cellular pathways 
depend on the intensity of DNA damage stimuli (Virag 
& Szabo 2002). PARP-1 activation in minimal genotoxic 
damage will enhance the DNA repair by interacting with 
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p53 protein, signaling cell-cycle arrest, and facilitating 
DNA repair enzymes to access the damaged DNA. PARP-1 
activation induces apoptotic cell death when DNA damage 
is irreparable or stronger damage happened. However, 
in an extensive DNA damage will cause over activation 
of PARP-1 that will lead to deplete of intracellular NAD, 
and therefore, trigger cell to undergo necrosis (Burkle 
2001). When the cells are severely deficient in energy, 
it is unable to proceed through apoptotic cell death since 
apoptosis is an energy-dependent process (Surjana et al. 
2010). Nicotinamide plays an important role in PARP-1 
activity for DNA repair and maintenance of the genomic 
stability and it is related to its function as a NAD+ 
precursor that involve in many biological processes 
(Litwack 2018) such as regulation of energy metabolism, 
DNA repair and transcription. 
Inhibition of PARP-1 also currently been studied to 
act as antitumor agent since PARP-1 inhibitors are able to 
boost the cytotoxic effects of alkylating agents (Rouleau 
et al. 2010) which they can enhance the chemo-sensitizers 
and radio-sensitizers in tumors therapy (Malyuchenko et 
al. 2015). Inhibition of PARP-1 may lead to the destruction 
of abnormal cells by suppressing the repair mechanism 
involved in DNA damage and cause failure to DNA repair. 
Thus, it will help to increase the effect of alkylating agent 
in causing breakage of DNA strands and eventually 
the death of the cell. PARP-1 inhibitors can be used as 
independent drug against tumors but the inhibitions do 
not always have direct cytotoxic effect on cell and it 
can be used with administration of other drug to treated 
several reported tumor such as in mice lymphoma, Hela 
cell, and lung cancer cell (Holl et al. 2000; Magan et al. 
2012; Mason et al. 2008). Moreover, it also have been 
reported that one of the PARP-1 inhibitors were shown to 
prevent recovery of the tumor cell after the potentially 
lethal damage and surpass the resistance (Liu et al. 2008).
Based on Malyuchenko et al. (2015), the first generation 
of typical PARP-1 inhibitor is nicotinamide which is 
one of the products of PARP-1 catalyzed reaction that 
can cause moderate inhibition to its activity. It has been 
reported in several studies that nicotinamide has inhibit 
PARP-1 activity (Allende-Castro et al. 2012; Knip et al. 
2000; Lee et al. 2008; Park et al. 2010; Virag & Szabo 
2002) in many type of disease and tumors in relation 
with NAD+ and ATP level cause by DNA strand breaks. 
Therefore, nicotinamide as an inhibitor of PARP-1 plays 
an important role in determining the cellular fate in 
response to DNA damage (Turunc Bayrakdar et al. 2014). 
By inhibition of PARP-1, NAD levels can be manipulated 
for the therapeutic potential. Since PARP-1 play an 
important role in detection and repair of both single-
stranded and double-stranded DNA breaks, its inhibition 
has been considered as a treatment to sensitize tumor 
cells to genotoxic stress such as induced by radiotherapy 
or chemotherapy. Moreover, telomere stability might also 
be influenced by PARP-1 activity (Boesten et al. 2013; 
Paul 2011) and since nicotinamide has been shown as 
PARP-1 inhibitor (Kjellen et al. 1985), therefore there 
might be some association between nicotinamide on 
the telomerase activity and telomere length mediated by 
PARP-1 mechanism.
EFFECTS OF NICOTINAMIDE ON TELOMERE AND 
TELOMERASE IN MYELOID CELLS
Telomerase activity have been studied and widely 
explored for their respond toward different kind of drug 
(Opitz 2005). These enzyme activities and the telomere 
maintenance are the markers of the proliferative 
potential of cells and have shown to be involved in cell 
immortalization and malignant transformation (Shay & 
Wright 2004). It is believed that increased telomerase 
activity found in human cancers prevents telomere 
length from shorten gradually and this allow the cancer 
cell to further proliferate out of the normal limits of 
cellular proliferation (Cao et al. 2008). 
Telomere is the repetitive DNA sequence that located 
at each end of the chromosome in order to maintain 
the chromosome stability and protect the chromosome 
from degradation or end-to-end fusion with the nearby 
chromosome (Bouffler et al. 1996). At each round of cell 
division, telomeres shorten progressively and according 
to limit the number of division for a cell to replicate. 
In the present study, the rate of telomere shortening was 
reduced in the presence of nicotinamide (Kang et al. 
2006) and it is possibly due to the shortening or damaged 
telomere that will activate the DNA-damage signal to 
lead to the cell life span extension.
While, telomerase is a ribonucleoprotein enzyme 
complex consisting of reverse transcriptase (hTERT), 
protein (hTP1) and RNA template for telomeric DNA 
synthesis (hTERC). This enzyme stabilizes telomere 
length and it has been suggested as a useful tumor marker 
for malignancy. hTERT is the major mechanism to 
regulate telomerase activity in human cells and in most 
cancer cells, it is specifically overexpressed (Horikawa 
& Barrett 2003; Matsubara et al. 2006). While, telomerase 
activity is present in over 90% of human tumors and it 
is absent in most somatic cells.  
According to study by Ida et al. (2009), nicotinic acid 
related compound including nicotinamide has inhibited 
the K562 cell proliferation by 50-90% and also induced 
differentiation in human acute promyelocytic leukemia 
HK-60 cells. Other than that, it was also shown to 
induce apoptosis in human cancer cells (Kauppinen et 
al. 2013). Several other studies have shown the effect 
of nicotinamide on the human SIRT1 which was 
completely inhibited and it leads to reduce the cell 
proliferation and activated the apoptosis (Audrito et 
al. 2011; Vaziri et al. 2001). In normal and cancerous 
cell in existence of damaged DNA will automatically 
activated the PARP-1 mechanism and by induction of 
nicotinamide will facilitated the DNA repair process 
while at the same time also affecting telomerase activity 
and telomere length regulation (Figure 1).
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FIGURE 1. Potential effects of nicotinamide towards telomerase and telomere regulation and association with 
PARP-1 mechanism in normal and cancer cells
K562 cell lines are the human cells that derived 
from 53 years old female who was a patient with blastic 
crisis of chronic myelogenous leukemia (CML) (Lozzio 
& Lozzio 1975). CML is one of the four major types of 
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leukemia disease that affects the myeloid cell. It has 
been reported as a myeloproliferative disorder due to 
the reciprocal translocation between chromosome 9 and 
22 called Philadelphia chromosome (Ph) that carried 
by the hematopoietic cell. These Ph chromosomes 
encode the BCR-ABL with constitutively active protein 
tyrosine kinase that is required for cell transformation. 
The fusion between these two chromosomes forming 
BCR-ABL oncogene has leading to uncontrolled cellular 
proliferation and also reduced apoptosis (Hazlehurst et 
al. 2009). CML cells are unable to function properly to 
fight infections and disease because they are not fully 
mature but when the bone marrow produces too much 
CML cells, it can interfere with the normal cell production 
and spill out of the bone marrow into the blood stream. 
It will prevent the bone marrow to make an adequate 
number of red blood cells, normal white blood cell and 
platelets that can cause the patient to be more susceptible 
to anemia, infection or to brushing and bleeding easily.
More than 90% of patient with CML were found 
to have the BCR-ABL tyrosine kinase and it cans be 
as a targeted molecular therapy in order to inhibit the 
oncogene activity from further proliferate out of control 
(Druker 2008; Melo & Barnes 2007; Yildirim et al. 
2016). During chronic phase, CML can be effectively 
treated with tyrosine kinase inhibitor (TKI) which is a 
type of drug that target the mutant BCR-ABL protein by 
blocking its effects that have been found in CML cell and it 
have been approves in clinical trial (Quintas-Cardama et 
al. 2007). It is referred as molecular targeted therapy due 
to the specific approach to block the effect of a specific 
protein that causes transformation of leukemia cell.
The therapy started with imatinib, is widely used 
as the standard first-line treatment (Druker et al. 
2001, 1996; Kantarjian et al. 2002) and has resulted in 
outstanding responses in the patient. Nevertheless, despite 
the excellent results with imatinib, a substantial fraction 
of patients eventually develop resistance to the drug and 
have to switch to the second-line therapy of TKI such 
as nilotinib and dasatinib to treat patient who become 
resistant or intolerant to imatinib (Hughes & White 2013; 
Leitner et al. 2011). It is debatably the best example of 
successful targeted CML treatment.
However, it is continued to exist as a challenging 
disease in order to treat the CML patient in a blast crisis 
(BC) phase even though the advance TKI therapy have 
been introduced (Pietarinen et al. 2015). When the TKI 
treatment are significantly less effective, it is causing the 
patient to be less favorably to respond toward the therapy 
is due to the more aggressive nature of advanced phase 
of CML. Even the original TKI such as imatinib did not 
show any toxicity effect to the body after the prolonged 
contact, but still the intake of imatinib gives several side 
effects to the patients and by switch the highly potent 
TKI such as nilotinib and dasatinib also could not be 
able to improve the overall survival (Hughes & White 
2013). Currently, there is no treatment options that are 
responding effectively in CML BC and it is require an 
identification of new drug therapies to treat the CML 
patients in a blast crisis.
A study by Shapira et al. (2012), have shown that 
the effect of these TKIs on telomerase activity is not 
necessarily dependent on their effect on BCR-ABL 
even though the telomerase activity have been reduced 
by 90% after been introduced with those TKIs agent 
compared to the untreated control. They are suggesting 
that the telomerase is not affected directly by these 
TKIs but rather through other so far unknown cellular 
proteins. Nilotinib have shown to have direct effect on 
telomerase activity where it have been reported to reduce 
telomerase activity and cause substantial decrease in 
hTERT expression which is part of enzyme telomerase 
(Shapira et al. 2012).
CONCLUSION
The role of nicotinamide as cancer preventive agent will 
be studied by investigating its effect in enhancing the effect 
of nilotinib which is the current treatment for patient with 
resistant to first-line treatment in CML. It has potential as 
a PARP-1 inhibitor and the ability to decelerate telomere 
shortening rate without detectable increase in telomerase 
activity may help to enhance the effect of nilotinib that 
have shown to have direct effect on telomerase activity. 
Nicotinamide may boost the effects of nilotinib in K562 
cell line and this may reduce the tumor growth or promote 
the tumor cells death. Therapeutic strategy for CML may 
be improved by understanding the role and potential 
of nicotinamide in telomere and telomerase status 
association with PARP-1 mechanism in myeloid cell line.
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